Regeneron Pharmaceuticals (REGN *) Aktienübersicht Regeneron Pharmaceuticals, Inc. erforscht, erfindet, entwickelt, produziert und vermarktet Medikamente zur Behandlung verschiedener Krankheiten weltweit. Mehr Details
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen REGN * Community Fair Values See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Regeneron Pharmaceuticals, Inc. Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Regeneron Pharmaceuticals Historische Aktienkurse Aktueller Aktienkurs US$9,835.00 52-Wochen-Hoch US$23,707.11 52-Wochen-Tief US$9,420.00 Beta 0.31 1 Monat Veränderung 3.15% 3 Monate Veränderung -24.41% 1 Jahr Veränderung -48.95% 3 Jahre Veränderung -18.25% 5 Jahre Veränderung -29.24% Veränderung seit IPO 8.37%
Aktuelle Nachrichten und Updates Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000 Growth Index
Regeneron Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 01, 2025 Jun 27 Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid
Regeneron Pharmaceuticals, Inc. Announces Interim Results from Ongoing Phase 2 Cloud Ridge Trial Confirm Potential to Improve the Quality of Semaglutide (Glp-1 Receptor Agonist)-Induced Weight Loss by Preserving Lean Mass Jun 03
Investor sentiment deteriorates as stock falls 18% May 30
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults May 30 Weitere Updates anzeigen Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000 Growth Index
Regeneron Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 01, 2025 Jun 27 Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid
Regeneron Pharmaceuticals, Inc. Announces Interim Results from Ongoing Phase 2 Cloud Ridge Trial Confirm Potential to Improve the Quality of Semaglutide (Glp-1 Receptor Agonist)-Induced Weight Loss by Preserving Lean Mass Jun 03
Investor sentiment deteriorates as stock falls 18% May 30
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults May 30
Regeneron Pharmaceuticals, Inc. Announces Initial Results from Two Cohorts of the Phase 1B Linker-Mm2 Trial Evaluating Linvoseltamab in Combination with Two Different Proteasome Inhibitors May 23
Undisclosed acquirer proposed to acquire 23andMe Holding Co. (OTCPK:MEHC.Q) for approximately $260 million. May 20
Upcoming dividend of US$0.88 per share May 13 Regeneron Pharmaceuticals, Inc. Announces 24 Abstracts on Dupixent (Dupilumab) Clinical Data and Real-World Analyses in Respiratory Diseases
Regeneron Pharmaceuticals, Inc. Declares Cash Dividend on the Common Stock and Class A Stock, Payable on June 6, 2025 Apr 30
First quarter 2025 earnings released: EPS: US$7.58 (vs US$6.70 in 1Q 2024) Apr 30
Regeneron Pharmaceuticals, Inc. Announces Approval in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma Apr 28
Regeneron Pharmaceuticals, Inc. Provides Update on EYLEA HD®? (aflibercept) Injection 8 mg Supplemental Biologics License Application Apr 19
Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts EYLEA HD (aflibercept) Injection 8 mg Apr 17
Biocon Biologics Ltd Announces Settlement and License Agreement with Regeneron Apr 16
Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2025 Apr 09
Regeneron Pharmaceuticals, Inc. and Sanofi Announce Ministry of Health, Labour and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) Mar 28
Regeneron Pharmaceuticals, Inc. to Report Q1, 2025 Results on Apr 29, 2025 Mar 26 Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad
Linvoseltamab Recommends for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma Feb 28
Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts odronextamab BLA for the Treatment of Relapsed/Refractory Follicular Lymphoma Feb 26
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP) Feb 18
U.S. Food and Drug Administration Accepts Linvoseltamab BLA for the Treatment of Relapsed/Refractory Multiple Myeloma Feb 12 Regeneron Pharmaceuticals, Inc. Announces First Presentation of Positive Results from the Phase 3 QUASAR Trial
Full year 2024 earnings released: EPS: US$40.90 (vs US$37.05 in FY 2023) Feb 04 Regeneron Pharmaceuticals, Inc. Approves the Initiation of A Quarterly Cash Dividend Program and Declares A Cash Dividend, Payable on March 20, 2025
Regeneron Pharmaceuticals, Inc. Announces Adjuvant Libtayo (Cemiplimab) Significantly Improves Disease-Free Survival After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma in Phase 3 Trial Jan 14
Gainey Mckenna & Egleston Files Class Action Lawsuit Against Regeneron Pharmaceuticals, Inc Jan 09
Regeneron Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 04, 2025 Jan 08
Regeneron Pharmaceuticals, Inc. to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-Concept Results Dec 19
Regeneron Pharmaceuticals, Inc. Announces EYLEA HD Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion Dec 18
Odronextamab Ash Presentations Underscore Impressive Potential in Early Lines of Treatment and Additional Types of Lymphoma Dec 10
Regeneron Pharmaceuticals, Inc. Announces that Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieve Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab Dec 09
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®? Nov 15
Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting Nov 13
Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis Nov 07
Third quarter 2024 earnings released: EPS: US$12.40 (vs US$9.48 in 3Q 2023) Nov 01
Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem Oct 19
Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China Sep 29
Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Sep 27
Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps Sep 14
Senior VP of Finance & CFO recently sold Mex$124m worth of stock Aug 30
Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma Aug 27
Regeneron Provides Update on Biologics License Application for Linvoseltamab Aug 21
Insider recently sold Mex$108m worth of stock Aug 13
Second quarter 2024 earnings released: EPS: US$13.25 (vs US$9.05 in 2Q 2023) Aug 02
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD Jul 04
Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Jun 29
Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jun 28
Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine Jun 27
Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma Jun 18
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation Jun 01
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28) May 24
Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine May 22
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent May 15
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks May 09
New minor risk - Shareholder dilution May 04
First quarter 2024 earnings released: EPS: US$6.70 (vs US$7.64 in 1Q 2023) May 03
Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares. May 03
Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma Apr 10 Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024
Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab Mar 27
Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol Mar 11
Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg Mar 09
Executive VP recently sold Mex$17m worth of stock Feb 27
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation Feb 24
Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review Feb 23
Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria Feb 16
Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma Feb 03 Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024
Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis Jan 26
Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab) Jan 17
Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024 Jan 06
Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes Dec 12
Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma Dec 08
Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023 Dec 07
Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial Nov 29
Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg Nov 02
Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss Oct 28 Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria
Regeneron Pharmaceuticals, Inc. Announces Clinical Data from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO Oct 16
Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) acquired remaining 91.65% stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders. Sep 27
Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders for approximately $100 million. Aug 11 Aktionärsrenditen REGN * MX Biotechs MX Markt 7D 0.3% 0% 0% 1Y -48.9% 0% 0%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: REGN * unter dem Niveau der Branche MX Biotechs , die im vergangenen Jahr eine Rendite von -4.6% erzielte.
Rendite vs. Markt: REGN * hinter dem Markt MX zurück, der im vergangenen Jahr eine Rendite von 3.8 erzielte.
Preisvolatilität Is REGN *'s price volatile compared to industry and market? REGN * volatility REGN * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stabiler Aktienkurs: Der Aktienkurs von REGN * war in den letzten 3 Monaten im Vergleich zum MX -Markt volatil.
Volatilität im Zeitverlauf: Unzureichende Daten , um die Volatilitätsveränderung von REGN * im vergangenen Jahr zu bestimmen.
Über das Unternehmen Regeneron Pharmaceuticals, Inc. erforscht, erfindet, entwickelt, produziert und vermarktet Medikamente zur Behandlung verschiedener Krankheiten weltweit. Zu den Produkten des Unternehmens gehören EYLEA-Injektion zur Behandlung der feuchten altersbedingten Makuladegeneration und des diabetischen Makulaödems, der myopischen choroidalen Neovaskularisation, der diabetischen Retinopathie, des neovaskulären Glaukoms und der Frühgeborenen-Retinopathie. Es bietet auch Dupixent Injektion zur Behandlung von atopischer Dermatitis und Asthma bei Erwachsenen und Kindern; Libtayo Injektion zur Behandlung von metastasierten oder lokal fortgeschrittenen Plattenepithelkarzinomen der Haut; Praluent Injektion für heterozygote familiäre Hypercholesterinämie (HoFH) oder klinische atherosklerotische kardiovaskuläre Erkrankungen bei Erwachsenen; REGEN-COV für Covid-19; und Kevzara Lösung zur Behandlung von rheumatoider Arthritis bei Erwachsenen.
Mehr anzeigen Regeneron Pharmaceuticals, Inc.'s Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Regeneron Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens? REGN * grundlegende Statistiken Marktanteil Mex$1.04t Gewinn(TTM ) Mex$84.62b Umsatz(TTM ) Mex$264.91b
12.2x
Kurs-Gewinn-Verhältnis 3.9x
Kurs-Umsatz-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) REGN * Gewinn- und Verlustrechnung (TTM ) Einnahmen US$14.09b Kosten der Einnahmen US$7.21b Bruttogewinn US$6.87b Sonstige Ausgaben US$2.37b Umsatz US$4.50b
Zuletzt gemeldete Gewinne
Mar 31, 2025
Datum des nächsten Gewinnberichts
Aug 01, 2025
Gewinn per Aktie (EPS) 42.58 Bruttomarge 48.80% Nettogewinnspanne 31.94% Schulden/Eigenkapital-Verhältnis 6.8%
Wie hat sich REGN * auf lange Sicht entwickelt?
Historische Performance und Vergleiche Dividenden 0.7%
Aktuelle Dividendenrendite
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/06/30 20:46 Aktienkurs zum Tagesende 2025/06/25 00:00 Gewinne 2025/03/31 Jährliche Einnahmen 2024/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr .
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github .
Analysten-Quellen Regeneron Pharmaceuticals, Inc. wird von 63 Analysten beobachtet. 25 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Jasper Hellweg Argus Research Company Brian Skorney Baird Ishan Majumdar Baptista Research
60 weitere Analysten anzeigen